Telemedicine Follow-up for Patients With Cervical Dystonia Treated With Neurotoxin Injections

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03969537

Enrollment

Registered

2019-05-31

Start date

2019-04-01

Completion date

2020-06-04

Last updated

2020-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Dystonia, Telemedicine

Keywords

Cervical Dystonia, Telemedicine, Telehealth

Brief summary

Many cervical dystonia (CD) patients are limited in their ability to travel to the clinic for follow-up in between injection visits. A telemedicine visit at the time of peak effectiveness of neurotoxin treatment may be valuable in informing the neurologist's choice of muscle selection and/or dose for the next injection visit. The primary objective of this study is to investigate both patient and physician satisfaction with the use of our telemedicine tool for this type of follow-up. After assessment of the subject, the neurologist will decide whether or not the telemedicine visit was informative to the upcoming injection visit. Subjects will answer questions at the end of the visit regarding their satisfaction with the follow-up and overall telemedicine communication. The principle investigator will complete a similar survey with additional questions about information gathered from the visit to assess the primary objective. A secure video communications platform will be used for the visit, which will occur 2-4 weeks after the patient's last neurotoxin injection (around the time of peak effectiveness). The investigating neurologist will remotely assess the patient and make notes for the next injection visit.

Interventions

OTHERTelemedicine follow-up visit

Study participants will experience two telemedicine (live audio/video) visits.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or female subjects of any race, aged 18 and above * Diagnosed with cervical dystonia and being treated with neurotoxin injections at Vanderbilt University Medical Center * The subject, or if appropriate their medical decision maker, is willing and able to provide written informed consent. * Email and internet access * Personal computing device with audio/video capability

Exclusion criteria

* Subjects for whom participation in the study may cause medical harm

Design outcomes

Primary

Measure	Time frame	Description
Patient Satisfaction with Telehealth	4 months	This questionnaire measures patient satisfaction with the telehealth visit scored 7 to 27

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026